Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Clinton Transition Co-Chair Tanden Offers Themes For A Drug Pricing Bill In 2017

Executive Summary

FAIR Drug Pricing Act, CAP proposal and Collins bill include viable legislative movers for next administration. CMS Acting Administrator Slavitt signals that Part B demo will move forward based on CBO score.

Advertisement

Related Content

Biopharma Goes 3 For 3 In Presidential Debates
Part B Demo Could Save $2.2 Bil., CBO Says; Blocking It Would Cost Less
Big Pharma’s Unlikely Price Pledge Leader
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?

Topics

Advertisement
UsernamePublicRestriction

Register

PS119314

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel